Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.

Autor: Raa DGT; Department of Internal Medicine, Gelderse Vallei, Ede, the Netherlands., van der Straten L; Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, the Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands.; Laboratory Medical Immunology, Department of Immunology, Erasmus MC, Rotterdam, The Netherlands., van Gelder M; Department of Hematology, Maastricht UMC, the Netherlands Maastricht., Kersting S; Department of Internal Medicine, HAGA hospital, Den Haag, the Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer hospital, Dordrecht, the Netherlands., Mous R; Department of Hematology, UMC Utrecht, the Netherlands Utrecht., van der Straaten HM; Department of Internal Medicine, St Jansdal hospital, Harderwijk, the Netherlands., Nijziel MR; Department of Internal Medicine, Catharina hospital, Eindhoven, the Netherlands., van der Spek E; Department of Internal Medicine, Rijnstate, Arnhem, the Netherlands., Posthuma EFM; Department of Internal Medicine, Reinier de Graaf hospital, Delft, the Netherlands.; Department of Hematology, Leiden Univerisity Medical Center, Leiden, the Netherlands., Visser HPJ; Department of Internal Medicine, Noordwest ziekenhuisgroep, Alkmaar, the Netherlands., van der Klift M; Department of Internal Medicine Amphia hospital, Breda, the Netherlands., de Heer K; Department of Internal Medicine, Flevo hospital, Almere, the Netherlands., Bellido M; Department of Hematology, Groningen University Medical Center, University of Groningen, Groningen, the Netherlands., Doorduijn JK; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands., Bruns AHW; Department of Hematology, UMC Utrecht, the Netherlands Utrecht., Raijmakers RAP; Department of Hematology, UMC Utrecht, the Netherlands Utrecht., Kater AP; Department of Hematology, Cancer Center Amsterdam, Lymphoma and Myeloma Center Amsterdam, Amsterdam UMC, Amsterdam, University of Amsterdam, Amsterdam, the Netherlands.
Jazyk: angličtina
Zdroj: Leukemia & lymphoma [Leuk Lymphoma] 2022 Oct; Vol. 63 (10), pp. 2276-2289. Date of Electronic Publication: 2022 Jun 23.
DOI: 10.1080/10428194.2022.2084731
Abstrakt: Management of patients with chronic lymphocytic leukemia (CLL) is changing due to considerable advances in the therapeutic armamentarium, and new therapies will possibly continue to emerge in the near future. Therefore, the CLL working group of the Dutch-Belgium Haemato-Oncology Cooperative Group for Adults in the Netherlands (HOVON) necessitated revising the Dutch CLL guidelines. The current guideline is based on the expert opinion of the HOVON CLL working group members and focusses on well-designed clinical trials taking into account efficacy with special emphasis on toxicity, treatment duration and treatment intensity. This article provides recommendations on diagnosis, treatment strategies in front-line and relapsed setting and provides supportive care measurements during novel-based therapies as well as for infectious CLL-related complications. The recommendations presented here are intended to provide guidance for the management of CLL patients in the Netherlands, and take into account the availability of treatment strategies at the time of this publication.
Databáze: MEDLINE
Nepřihlášeným uživatelům se plný text nezobrazuje